Given our findings on DMBT1 co-expression with ACE2 in lung AT2 cells, as well as its reported binding to multiple viruses, we suggest that targeting DMBT1 using soluble peptides [54] or by antibody-based neutralization may represent a viable strategy to counteract SARS-CoV-2 infection and ameliorate COVID-19. The gene discussed is ACE2; the disease is COVID-19.